{"contentid": 488337, "importid": NaN, "name": "Moderna shows lasting vaccine efficacy and hope for boosters", "introduction": "East Coast, USA-based mRNA specialist Moderna has announced positive clinical trial news from its coronavirus vaccine program.", "content": "<p><span style=\"font-weight: 400;\">East Coast, USA-based mRNA specialist Moderna (Nasdaq: MRNA) has announced positive clinical trial news from its coronavirus vaccine program.</span></p>\n<p><span style=\"font-weight: 400;\">The firm said its vaccine mRNA-1273, which is approved and in use in multiple jurisdictions including in the UK, USA and Europe, retained a high level of efficacy after six months.</span></p>\n<p><span style=\"font-weight: 400;\">The data also reconfirm the previously-reported high level of vaccine efficacy starting two weeks after the second dose - 90% against all cases of COVID-19, and greater than 95% against severe cases.</span></p>\n<p><span style=\"font-weight: 400;\">Over 132 million doses of Moderna's coronavirus vaccine have been delivered, with over 85 million doses having been administered in the USA.</span></p>\n<p><span style=\"font-weight: 400;\">The firm continues to study the product in the Phase III COVE study.</span></p>\n<h2>Hope for variant boosters</h2>\n<p><span style=\"font-weight: 400;\">While other approved vaccines have been hit by setbacks related to safety, Moderna&rsquo;s option has continued to report positive data from its ongoing clinical trials.</span></p>\n<p><span style=\"font-weight: 400;\">Both AstraZeneca (LSE: AZN) and Johnson &amp; Johnson (NYSE: JNJ) are facing scrutiny over a very small number of severe blood clotting cases which public health authorities have linked to their respective vaccines.</span></p>\n<p><span style=\"font-weight: 400;\">Moderna, meanwhile, has reported further positive news from a pre-clinical study of its variant-specific vaccine candidates, which show its boosters increase neutralizing titers against SARS-CoV-2 variants of concern.&nbsp;</span></p>\n<p><span style=\"font-weight: 400;\">The company&rsquo;s shares were lifted over 13% following the announcement on Tuesday.</span></p>\n<p><span style=\"font-weight: 400;\">Chief executive St&eacute;phane Bancel said: &ldquo;We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase II/III study of our COVID-19 vaccine in adolescents.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">He added: &ldquo;The new pre-clinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants. Moderna will make as many updates to our COVID-19 vaccine as necessary until the pandemic is under control.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">The firm has published the data on antibody persistence after six months in The New England Journal of Medicine.</span></p>", "date": "2021-04-14 11:40:00", "meta_title": NaN, "meta_keywords": "vaccine, Moderna, data, clinical, positive, efficacy, study, coronavirus, news, boosters, cases, firm, COVID-, variant-specific, candidates, trial, mRNA", "meta_description": "East Coast, USA-based mRNA specialist Moderna has presented positive clinical trial news from its coronavirus vaccine program.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-14 11:39:12", "updated": "2021-04-14 12:00:38", "access": NaN, "url": "https://www.thepharmaletter.com/article/moderna-shows-lasting-vaccine-efficacy-and-hope-for-boosters", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "moderna_therapeutics_large.jpg", "image2id": "moderna_therapeutics_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "USA", "company_tag": "Moderna", "drug_tag": "mRNA-1273", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-14 11:40:00"}